Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma

The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.

Read more: https://www.healio.com/news/hematology-oncology/20220614/bortezomib-extends-survival-of-children-with-newly-diagnosed-tcell-lymphoblastic-lymphoma